Repercusión cardiovascular de la infección por el nuevo coronavirus SARS-CoV-2 (COVID-19)

Francisco L. Moreno-Martínez; Frank L. Moreno-López; Ricardo Oroz Moreno

Authors

Francisco L. Moreno-Martínez http://orcid.org/0000-0001-5860-8527
Frank L. Moreno-López http://orcid.org/0000-0001-9237-8016
Ricardo Oroz Moreno http://orcid.org/0000-0003-2362-3721

Abstract

Cardiovascular effects of new coronavirus infection SARS-CoV-2 (COVID-19)

Downloads

Download data is not yet available.

References

1. Palacios Cruz M, Santos E, Velázquez Cervantes MA, León Juárez M. COVID-19, una emergencia de salud pública mundial. Rev Clin Esp [Internet]. 2020 [En línea 20 Mar 2020]. Disponible en: https://doi.org/10.1016/j.rce.2020.03.001

2. World Health Organization. 2019-nCoV outbreak is an emergency of international concern [Internet, publicado 31 Ene 2020]. World Health Organization, Regional Office for Europe [citado 28 Mar 2020]. Disponible en: http://www.euro.who.int/en/health-topics/health-emergencies/international-health-regulations/news/news/2020/2/2019-ncov-outbreak-is-an-emergency-of-international-concern

3. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet, publicado 11 Mar 2020]. World Health Organization [citado 28 Mar 2020]. Disponible en: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020

4. Heymann DL, Shindo N; WHO Scientific and Technical Advisory Group for Infectious Hazards. COVID-19: what is next for public health? Lancet. 2020;395(10224):542-5.

5. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-23.

6. Coronavirus Resource Center. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [Internet]. Johns Hopkins University of Medicine [citado 12 Abr 2020]; 2020. Disponible en: https://coronavirus.jhu.edu/map.html

7. World Health Organization. Coronavirus (COVID-19) – WHO Health Emergency Dashboard [Internet]. 2020 [citado 12 Abr 2020]. Disponible en: https://covid19.who.int/

8. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14(3):247-50.

9. Paules CI, Marston HD, Fauci AS. Coronavirus Infections-More Than Just the Common Cold. JAMA. 2020;323(8):707-8.

10. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181-92.

11. Cossarizza A, De Biasi S, Guaraldi G, Girardis M, Mussini C; Modena Covid-19 Working Group (MoCo19)#. SARS-CoV-2, the Virus that Causes COVID-19: Cytometry and the New Challenge for Global Health. Cytometry A. 2020;97(4):340-3.

12. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res [Internet]. 2020 [En línea 13 Mar 2020];7(1):11. Disponible en: https://doi.org/10.1186/s40779-020-00240-0

13. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564-7.

14. Huang Y, Chen S, Yang Z, Guan W, Liu D, Lin Z, et al. SARS-CoV-2 Viral Load in Clinical Samples of Critically Ill Patients. Am J Respir Crit Care Med. 2020 [En línea 15 Abr 2020]. Disponible en: https://doi.org/10.1164/rccm.202003-0572le

15. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation [Internet]. 2020 [En línea 21 Mar 2020]. Disponible en: http://doi.org/10.1161/CIRCULATIONAHA.120.046941

16. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177-9.

17. Pérez Assef A, Rivero Martínez HB, Pereda González R, Breto García A, Piloto Padrón M, Oviedo Rodríguez R. Protocolo para el tratamiento de la enfermedad por COVID-19 (SARS-CoV-2) en pacientes obstétricas ingresadas en cuidados intensivos. Rev Cuban Med Int Emerg [Internet]. 2020 [10 Abr 2020];19(2):e745. Disponible en: http://www.revmie.sld.cu/index.php/mie/article/view/745/pdf

18. Yang H, Wang C, Poon LC. Novel coronavirus infection and pregnancy. Ultrasound Obstet Gynecol. 2020;55(4):435-7.

19. Chen D, Yang H, Cao Y, Cheng W, Duan T, Fan C, et al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. Int J Gynaecol Obstet. 2020;149(2):130-6.

20. Kimberlin DW, Stagno S. Can SARS-CoV-2 Infection Be Acquired In Utero?: More Definitive Evidence Is Needed. JAMA [Internet]. 2020 [En línea 26 Mar 2020]. Disponible en: https://doi.org/10.1001/jama.2020.4868

21. Liu W, Wang J, Li W, Zhou Z, Liu S, Rong Z. Clinical characteristics of 19 neonates born to mothers with COVID-19. Front Med [Internet]. 2020 [En línea 13 Abr 2020]. Disponible en: https://doi.org/10.1007/s11684-020-0772-y

22. Pérez G. Coronavirus y su impacto cardiovascular [Internet, publicado 22 Mar 2020]. Sociedad Interamericana de Cardiología [citado 30 Mar 2020]. Disponible en: http://www.siacardio.com/novedades/covid-19/coronavirus-y-su-impacto-cardiovascular/

23. Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and Ageusia: Common Findings in COVID-19 Patients [Internet]. Laryngoscope. 2020 [En línea 1 Abr 2020]. Disponible en: https://doi.org/10.1002/lary.28692

24. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4.

25. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol [Internet]. 2020 [En línea 27 Mar 2020]. Disponible en: http://doi.org/10.1001/jamacardio.2020.1096

26. Siddiqi HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. J Heart Lung Transplant [Internet]. 2020 [En línea 20 Mar 2020]. Disponible en: https://doi.org/10.1016/j.healun.2020.03.012

27. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J [Internet]. 2020 [En línea 28 Mar 2020]:ehaa231. Disponible en: https://doi.org/10.1093/eurheartj/ehaa231

28. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.

29. Yang C, Jin Z. An Acute Respiratory Infection Runs Into the Most Common Noncommunicable Epidemic-COVID-19 and Cardiovascular Diseases. JAMA Cardiol [Internet]. 2020. [En línea 25 Mar 2020]. Disponible en: http://doi.org/10.1001/jamacardio.2020.0934

30. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.

31. Bonow RO, Fonarow GC, O'Gara PT, Yancy CW. Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. JAMA Cardiol [Internet]. 2020 [En línea 27 Mar 2020]. Disponible en: http://doi.org/10.1001/jamacardio.2020.1105

32. @Cardio_delaGuia (Fernando de la Guía). Hipótesis de Lesión Cardíaca Aguda #Covid19 #coronavirus [Internet]. Publicación en Twitter 19 Mar 2020 [citado 11 Abr 2020]. Obtenido de: https://twitter.com/Cardio_delaGuia/status/1240584448241852416

33. Chen YD, Li YZ, Liu XH, Zhou H. Potential pathophysiological mechanisms underlying COVID-19-induced myocardial injury. Chin J Pathophysiol. 2020;36(3):573-6.

34. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-60.

35. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol [Internet]. 2020 [En línea 27 Mar 2020]:e201017. Disponible en: https://doi.org/10.1001/jamacardio.2020.1017

36. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol [Internet]. 2020 [En línea 25 Mar 2020]:e200950. Disponible en: http://doi.org/10.1001/jamacardio.2020.0950

37. Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E, et al. The variety of cardiovascular presentations of COVID-19. Circulation [Internet]. 2020. [En línea 3 Abr 2020]. Disponible en: http://doi.org/10.1161/CIRCULATIONAHA.120.047164

38. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264-74.

39. Hulot JS. COVID-19 in patients with cardiovascular diseases. Arch Cardiovasc Dis. 2020;113(4):225-6.

40. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63(3):457-60.

41. Fung G, Luo H, Qiu Y, Yang D, McManus B. Myocarditis. Circ Res. 2016;118(3):496-514.

42. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. Eur Heart J [Internet]. 2020 [En línea 16 Mar 2020]:ehaa190. Disponible en: https://doi.org/10.1093/eurheartj/ehaa190

43. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol [Internet]. 2020 [En línea 27 Mar 2020]. Disponible en: https://doi.org/10.1001/jamacardio.2020.1286

44. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231-64.

45. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med [Internet]. 2020 [En línea 23 Abr 2020];382(17):e38. Disponible en: https://doi.org/10.1056/nejmc2007575

46. Gauna ME, Bernava JL. Recomendaciones diagnósticas y terapéuticas ante la Respuesta Inmune Trombótica Asociada a Covid-19 (RITAC). CorSalud [Internet]. 2020 [citado 1 Abr 2020];12(1):60-3. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/view/615/1110

47. Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford). 2019;58(1):5-17.

48. Karakike E, Giamarellos-Bourboulis EJ. Macrophage Activation-Like Syndrome: A distinct entity leading to early death in sepsis. Front Immunol [Internet]. 2019 [citado 10 Abr 2020];10:55. Disponible en: https://doi.org/10.3389/fimmu.2019.00055

49. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517-28.

50. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-39.

51. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(14):e698-e800.

52. Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. Int J Cardiol [Internet]. 2020 [En línea 28 Mar 2020]. Disponible en: https://doi.org/10.1016/j.ijcard.2020.03.063

53. Romaguera R, Cruz-González I, Jurado-Román A, Ojeda S, Fernández-Cisnal A, Jorge-Pérez P, et al. Consideraciones sobre el abordaje invasivo de la cardiopatía isquémica y estructural durante el brote de coronavirus COVID-19. Documento de consenso de la Asociación de Cardiología Intervencionista y la Asociación de Cardiopatía Isquémica de la Sociedad Española de Cardiología. REC Interv Cardiol [Internet]. 2020 [En línea 25 Mar 2020]. Disponible en: https://doi.org/10.24875/RECIC.M20000119

54. Romaguera R, Cruz-González I, Ojeda S, Jiménez-Candil J, Calvo D, García Seara J, et al. Gestión de las salas de procedimientos invasivos cardiológicos durante el brote de coronavirus COVID-19. Documento de consenso de la Asociación de Cardiología Intervencionista y la Asociación del Ritmo Cardiaco de la Sociedad Española de Cardiología. REC Interv Cardiol [Internet]. 2020 [En línea 27 Mar 2020]. Disponible en: https://doi.org/10.24875/RECIC.M20000114

55. Welt FGP, Shah PB, Aronow HD, Bortnick AE, Henry TD, Sherwood MW, et al. Catheterization laboratory considerations during the Coronavirus (COVID-19) Pandemic: From ACC's Interventional Council and SCAI. J Am Coll Cardiol [Internet]. 2020 [En línea 19 Mar 2020]. Disponible en: http://doi.org/10.1016/j.jacc.2020.03.021

56. Han Y, Zeng H, Jiang H, Yang Y, Yuan Z, Cheng X, et al. CSC Expert Consensus on Principles of Clinical Management of patients with severe emergent cardiovascular diseases during the COVID-19 Epidemic. Circulation [Internet]. 2020. [En línea 27 Mar 2020]. Disponible en: http://doi.org/10.1161/CIRCULATIONAHA.120.047011

57. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315.

58. Gómez Guindal JA. Protocolo de atención a pacientes con síndrome coronario agudo en el Hospital de Fuerteventura durante la pandemia de COVID-19. CorSalud [Internet]. 2020 [citado 1 Abr 2020];12(1):109-113. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/view/604/1111

59. Patel MR, Calhoon JH, Dehmer GJ, Grantham JA, Maddox TM, Maron DJ, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 Appropriate Use Criteria for Coronary Revascularization in Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2017;69(5):570-91.

60. Barja LD, Fitz Maurice M, Chávez González E. Hidroxicloroquina y azitromicina: riesgo cardiovascular, prolongación de QTc y muerte súbita en el nuevo escenario de la pandemia por COVID-19. CorSalud [Internet]. 2020 [citado 31 Mar 2020];12(1):54-59. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/view/601/1108

61. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med [Internet]. 2020 [En línea 3 Mar 2020]. Disponible en: https://doi.org/10.1007/s00134-020-05991-x

62. Vetta F, Vetta G, Marinaccio L. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Vicious Circle. J Cardiol Cardiovasc Res [Internet]. 2020 [citado 12 Abr 2020];1(2):1-12. Disponible en: https://maplespub.com/webroot/files/Coronavirus-Disease-2019-covid-19-and-Cardiovascular-Disease-A-Vicious-Circle_1585652470.pdf

63. Touyz RM, Li H, Delles C. ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19. Clin Sci (Lond). 2020;134(7):747-50.

64. Henry C, Zaizafoun M, Stock E, Ghamande S, Arroliga AC, White HD. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proc (Bayl Univ Med Cent). 2018;31(4):419-23.

65. Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc [Internet]. 2020 [En línea 1 Abr 2020];9(7):e016219. Disponible en: https://doi.org/10.1161/jaha.120.016219

66. South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5):H1084-90.

67. Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G. Angiotensin-Converting Enzyme 2 and antihypertensives (angiotensin receptor blockers and angiotensin-converting enzyme inhibitors) in Coronavirus Disease 2019. Mayo Clin Proc [Internet]. 2020 [En línea 30 Mar 2020]. Disponible en: https://doi.org/10.1016/j.mayocp.2020.03.026

68. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875-9.

69. Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hypertension [Internet]. 2020. [En línea 25 Mar 2020]. Disponible en: https://doi.org/10.1161/hypertensionaha.120.15082

70. Chapman AR, Bularga A, Mills NL. High-Sensitivity cardiac troponin can be an ally in the fight against COVID-19. Circulation [Internet]. 2020. [En línea 6 Abr 2020]. Disponible en: http://doi.org/10.1161/CIRCULATIONAHA.120.047008

71. Wang J, Xu H, Yang X, Zhao D, Liu S, Sun X, et al. Cardiac complications associated with the influenza viruses A subtype H7N9 or pandemic H1N1 in critically ill patients under intensive care. Braz J Infect Dis. 2017;21(1):12-8.